Comparing Atorvastatin and Rosuvastatin's effects on Vitamin D levels in heart patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of Atorvastatin versus Rosuvastatin on Vitamin D levels in patients diagnosed with acute coronary syndrome. A total of 152 patients with normal Vitamin D levels will be randomly assigned to receive either Atorvastatin (40 mg/day) or Rosuvastatin (20 mg/day) for a duration of six months. The primary outcome will be the change in 25-hydroxy Vitamin D levels after the treatment period. This study aims to provide insights into the relationship between statin therapy and Vitamin D levels in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Acute Coronary Syndrome

25 OH-Vitamin D levels between 30-70ng/ml

Exclusion Criteria:

Hypercalcemia

hypocalcemia

pregnancy

lactation

hypersensitivity to statins

hypothyroidism

Deranged LFTs \& RFTs

Use of following within last 3 months (Vitamin D Supplements, lipid lowering drugs, anti-obesity drugs, corticosteroids)

Where it's running

• King Edward Medical University
  Lahore, Punjab Province, Pakistan Recruiting

Study contacts

• Principal investigator: Ali Hussnain — King Edward Medical University
• Study coordinator: Ali Hussnain
• Email: ahshah12@hotmail.com
• Phone: +923317641096

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Aspirin 50 mg vs 100 mg with a P2Y12 inhibitor after PCI

  This trial tests whether a 50 mg daily aspirin dose, when used with a P2Y12 inhibitor after PCI, works as well as 100 mg with similar safety for people staying on DAPT for 12 months.

  Recruiting Jilin University · Changchun, Jilin · NCT07846462

• Early Triple Lipid-Lowering Therapy After ACS

  This trial tests whether adding bempedoic acid to high-intensity statin and ezetimibe within 72 hours after PCI helps more adults with acute coronary syndrome reach LDL-C goals than the standard two-drug approach.

  Recruiting Phase 4 Taipei Medical University Hospital · Taipei, Taipei City · NCT07824323

• Smartphone AI help for prehospital ECG readings

  This study tests whether using a smartphone AI (GPT-4o) to help prehospital providers read 12-lead ECGs improves accuracy in diagnosing acute coronary syndromes and related conditions.

  Recruiting École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Murten/Morat, Canton of Fribourg · NCT07810686

• Early single antiplatelet therapy after IVUS-guided PCI in ACS

  This study tests whether stopping aspirin early and continuing a potent P2Y12 inhibitor alone is safe and effective after IVUS-guided PCI in people with acute coronary syndrome.

  Recruiting Phase 4 Gyeongsang National University Hospital · Jinju, Gyeongsangnam-do · NCT07684742

• Local and systemic macrophage activation in coronary and peripheral artery disease

  This study tests whether macrophage activity inside coronary and peripheral arteries relates to circulating monocyte subtypes in people with stable and acute artery disease.

  Recruiting Maria Cecilia Hospital · Cotignola, Ravenna · NCT07588295

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.